Antibody Drug Conjugates: Link Your Antibody To Its Fullest Potential
Samsung Biologics, a leading Contract Development and Manufacturing Organization (CDMO), is expanding into the production of Antibody-Drug Conjugates (ADCs). Leveraging its existing expertise and state-of-the-art facilities, the company offers a comprehensive suite of ADC services, including development, manufacturing, and supply chain management. Their integrated approach combines antibody production, conjugation development, and manufacturing under one roof, minimizing risk and expediting time to market.
Key benefits include:
- Flexible batch size : 30 L to 500 L conjugation train
- Drug product : Aseptic fill/finish and lyophilization (Grade A isolator)
- Full-scope laboratories for development, QC, and MSAT
- Utilization of antibody manufacturing facility and expertise
Download the brochure to learn more about how Samsung Biologics can help you bring your ADC therapy to market faster.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.